Pulnovo Medical secures $100 million in funding led by Medtronic
Pulnovo Medical secures $100 million in funding led by Medtronic
Pulnovo Medical, a pioneer in interventional cardiology, recently secured $100 million in an oversubscribed strategic financing round.
This major investment was led by Medtronic, a global leader in medical technology.
Along with the funding, the two companies entered a commercial agreement to explore future market opportunities.
Founded in 2013, Pulnovo specializes in Pulmonary Artery Denervation (PADN), a minimally invasive procedure targeting nerves to treat pulmonary hypertension.
In the United States, their PADN system has earned FDA Breakthrough Device designation, and the company is currently conducting two IDE trials led by Dr.
Gregg Stone.
The new capital will be used to accelerate clinical trials and enhance international commercial infrastructure, signaling strong institutional confidence in their proprietary technology.
